
In a study conducted the combined treatment of temozolomide (TMZ) and PD-1/L1 inhibitors was evaluated for non-small cell lung cancer (NSCLC) with brain metastases (BM). With 42 patients enrolled, the regimen demonstrated an objective response ratio (ORR) of 26.19%. Intracranial and extracranial lesion ORR were 6% and 20% respectively, and the disease control rate (DCR) was 64.29%. The mean progression-free survival (PFS) and overall survival (OS) were approximately 4 and 8.5 months. Efficient outcomes were associated with the diagnosis-Specific Graded Prognostic Assessment (ds-GPA) score, and the manageable toxicity suggested the regimen's potential.
Like
Save
Share